Economic analysis of active surveillance for localized prostate cancer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Active surveillance is gaining wider acceptance in the urologic community as an effective treatment option for patients with low-risk prostate cancer. The purpose of this review is to analyze the economics of active surveillance in comparison with other therapies. RECENT FINDINGS: Evaluating the economics of active surveillance in patients with low-risk prostate cancer is constrained by a prolonged natural history of disease. Recent cost model studies using hypothetical patients with low-risk prostate cancer showed that the estimated direct cost of active surveillance over long term was the lowest compared with direct costs of immediate treatment with radical prostatectomy, external beam radiation therapy, primary androgen deprivation therapy or brachytherapy. Active surveillance is associated with more quality-adjusted life years than immediate therapies with similar or lower lifetime costs. Physician reimbursement for active surveillance exceeded that from upfront radical prostatectomy after 3-5 years of follow-up and may be an important driving factor for physicians to practice active surveillance. SUMMARY: Active surveillance appears to reduce prostate cancer healthcare expenditure by reducing the number of costly therapies. Results from clinical trials will allow the measurement of the true economic value of active surveillance in the future.

Original languageEnglish (US)
Pages (from-to)247-253
Number of pages7
JournalCurrent Opinion in Urology
Volume22
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Prostatic Neoplasms
Economics
Prostatectomy
Costs and Cost Analysis
Physicians
Therapeutics
Quality-Adjusted Life Years
Brachytherapy
Health Expenditures
Health Care Costs
Androgens
Radiotherapy
Clinical Trials
Delivery of Health Care

Keywords

  • economics
  • healthcare cost
  • prostate cancer
  • watchful waiting

ASJC Scopus subject areas

  • Urology

Cite this

Economic analysis of active surveillance for localized prostate cancer. / Kim, Sun Ii; Dall'Era, Marc; Evans, Christopher P.

In: Current Opinion in Urology, Vol. 22, No. 3, 05.2012, p. 247-253.

Research output: Contribution to journalArticle

@article{aae4c5c0a1b74612b21e837c015de699,
title = "Economic analysis of active surveillance for localized prostate cancer",
abstract = "PURPOSE OF REVIEW: Active surveillance is gaining wider acceptance in the urologic community as an effective treatment option for patients with low-risk prostate cancer. The purpose of this review is to analyze the economics of active surveillance in comparison with other therapies. RECENT FINDINGS: Evaluating the economics of active surveillance in patients with low-risk prostate cancer is constrained by a prolonged natural history of disease. Recent cost model studies using hypothetical patients with low-risk prostate cancer showed that the estimated direct cost of active surveillance over long term was the lowest compared with direct costs of immediate treatment with radical prostatectomy, external beam radiation therapy, primary androgen deprivation therapy or brachytherapy. Active surveillance is associated with more quality-adjusted life years than immediate therapies with similar or lower lifetime costs. Physician reimbursement for active surveillance exceeded that from upfront radical prostatectomy after 3-5 years of follow-up and may be an important driving factor for physicians to practice active surveillance. SUMMARY: Active surveillance appears to reduce prostate cancer healthcare expenditure by reducing the number of costly therapies. Results from clinical trials will allow the measurement of the true economic value of active surveillance in the future.",
keywords = "economics, healthcare cost, prostate cancer, watchful waiting",
author = "Kim, {Sun Ii} and Marc Dall'Era and Evans, {Christopher P}",
year = "2012",
month = "5",
doi = "10.1097/MOU.0b013e328351dd32",
language = "English (US)",
volume = "22",
pages = "247--253",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Economic analysis of active surveillance for localized prostate cancer

AU - Kim, Sun Ii

AU - Dall'Era, Marc

AU - Evans, Christopher P

PY - 2012/5

Y1 - 2012/5

N2 - PURPOSE OF REVIEW: Active surveillance is gaining wider acceptance in the urologic community as an effective treatment option for patients with low-risk prostate cancer. The purpose of this review is to analyze the economics of active surveillance in comparison with other therapies. RECENT FINDINGS: Evaluating the economics of active surveillance in patients with low-risk prostate cancer is constrained by a prolonged natural history of disease. Recent cost model studies using hypothetical patients with low-risk prostate cancer showed that the estimated direct cost of active surveillance over long term was the lowest compared with direct costs of immediate treatment with radical prostatectomy, external beam radiation therapy, primary androgen deprivation therapy or brachytherapy. Active surveillance is associated with more quality-adjusted life years than immediate therapies with similar or lower lifetime costs. Physician reimbursement for active surveillance exceeded that from upfront radical prostatectomy after 3-5 years of follow-up and may be an important driving factor for physicians to practice active surveillance. SUMMARY: Active surveillance appears to reduce prostate cancer healthcare expenditure by reducing the number of costly therapies. Results from clinical trials will allow the measurement of the true economic value of active surveillance in the future.

AB - PURPOSE OF REVIEW: Active surveillance is gaining wider acceptance in the urologic community as an effective treatment option for patients with low-risk prostate cancer. The purpose of this review is to analyze the economics of active surveillance in comparison with other therapies. RECENT FINDINGS: Evaluating the economics of active surveillance in patients with low-risk prostate cancer is constrained by a prolonged natural history of disease. Recent cost model studies using hypothetical patients with low-risk prostate cancer showed that the estimated direct cost of active surveillance over long term was the lowest compared with direct costs of immediate treatment with radical prostatectomy, external beam radiation therapy, primary androgen deprivation therapy or brachytherapy. Active surveillance is associated with more quality-adjusted life years than immediate therapies with similar or lower lifetime costs. Physician reimbursement for active surveillance exceeded that from upfront radical prostatectomy after 3-5 years of follow-up and may be an important driving factor for physicians to practice active surveillance. SUMMARY: Active surveillance appears to reduce prostate cancer healthcare expenditure by reducing the number of costly therapies. Results from clinical trials will allow the measurement of the true economic value of active surveillance in the future.

KW - economics

KW - healthcare cost

KW - prostate cancer

KW - watchful waiting

UR - http://www.scopus.com/inward/record.url?scp=84862827703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862827703&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e328351dd32

DO - 10.1097/MOU.0b013e328351dd32

M3 - Article

C2 - 22388666

AN - SCOPUS:84862827703

VL - 22

SP - 247

EP - 253

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 3

ER -